Merck is bridging its patent cliffs with massive acquisitions
- KEYTRUDA QLEX is defending the core oncology franchise, generating $463 million in recent quarterly sales.
- WINREVAIR sales hit $588 million in Q2 2026, marking it as a clear cardiovascular growth driver.
- The FDA approved LIPFENDRA, an oral PCSK9 inhibitor that adds a massive new primary care asset to the portfolio.
- Merck deployed $16 billion in the first half of 2026 to acquire Terns and Cidara.
- JANUVIA and BRIDION lose U.S. exclusivity in mid-2026, but the BRIDION decline is expected to be slower than previously modeled.
A portfolio transition gaining traction
Merck is a portfolio in transition, but the bridge to its future is getting stronger. KEYTRUDA remains the core profit engine, while WINREVAIR is proving to be a massive cardiovascular growth driver with $588 million in Q2 2026 sales. The recent FDA approval of LIPFENDRA adds another major asset to this secondary pillar.
The challenge remains timing. JANUVIA and JANUMET lost U.S. market exclusivity in May 2026, and BRIDION follows in July 2026. Loss of exclusivity means cheaper generic drugs enter the market, usually causing sales to fall quickly.
The bull case is strengthening because Merck is successfully defending its core with KEYTRUDA QLEX and building new revenue streams fast enough to offset older product losses. The company is also heavily augmenting its pipeline via multi-billion dollar acquisitions like Terns and Cidara.
The bear case centers on whether primary care doctors will adopt LIPFENDRA quickly enough and how new international pricing laws will compress margins. If new launches plateau or acquired assets fail, the eventual KEYTRUDA patent cliff later this decade will still leave a large revenue gap.
Science, sales, and reinvestment
Merck discovers, develops, makes, and sells medicines and vaccines. Most sales come from human health products sold to drug wholesalers, retailers, hospitals, governments, and health plans. A smaller but growing Animal Health business sells medicines, vaccines, and monitoring tools for livestock and pets.
The model works best when Merck owns protected drugs with strong demand. Patents and regulatory exclusivity help protect pricing and market share for a time. When that protection ends, generic or competing products can take a large share quickly.
Merck is actively preparing for that cycle. It deployed $16 billion in the first half of 2026 to acquire Terns and Cidara, aiming to augment its pipeline. Its 2025 Restructuring Program is also meant to generate about $3.0 billion in annual savings by the end of 2027, which the company is reinvesting into these new growth areas.
That plan adds discipline, but it also shows the pressure. Merck must keep funding expensive research while replacing revenue from older products and handling new international pricing pressures, like Germany's recent health care reform law.
The drugs that matter most
KEYTRUDA
KEYTRUDA is Merck's lead cancer drug and the main profit engine. Management has framed the drug as central to growth through its peak years.
Keytruda Qlex
Keytruda Qlex is the subcutaneous version of KEYTRUDA, given by injection under the skin. It generated $463 million in Q2 2026 and helps defend the franchise.
WINREVAIR
WINREVAIR treats pulmonary arterial hypertension. Sales reached $588 million in Q2 2026, making it the clearest new launch success so far.
LIPFENDRA
LIPFENDRA is a newly approved oral PCSK9 inhibitor to help reduce LDL cholesterol. It serves as a massive new primary care asset for the cardiometabolic division.
GARDASIL and GARDASIL 9
GARDASIL is Merck's HPV vaccine franchise. It stabilized in Q2 2026 with 3 percent global growth after suffering sharp demand drops in China.
JANUVIA and JANUMET
JANUVIA and JANUMET are diabetes products now facing generic competition. They lost U.S. market exclusivity in May 2026.
BRIDION
BRIDION is used to reverse certain anesthesia effects after surgery. It loses U.S. market exclusivity in July 2026, though management expects a slower decline than previously modeled.
Animal Health
Animal Health sells veterinary medicines, vaccines, and health management tools. It continues to deliver solid sales growth across livestock and companion animal portfolios.
Mostly human health
Mix is based on recent reportable segment sales. The human health division drives the vast majority of revenue, heavily weighted toward oncology and cardiometabolic drugs.
What could break the story
LIPFENDRA adoption stalls
High impact · Medium oddsThe bull case requires LIPFENDRA to scale into a massive growth driver. If primary care physician inertia and access hurdles limit its uptake against entrenched generic statins and injectable PCSK9s, Merck will lose a key growth pillar.
Mid-2026 generic shock
High impact · High oddsJANUVIA and JANUMET lose U.S. exclusivity in May 2026, and BRIDION follows in July 2026. While the BRIDION decline might be slower than expected, the first full quarter after generic entry will show exactly how steep the revenue hit really is.
WINREVAIR growth slows too soon
High impact · Medium oddsWINREVAIR is a strong new launch proof point, but investors still do not know its steady run rate. If the drug plateaus near current levels, it may not offset the losses from older franchises.
Pricing pressure expands
Medium impact · High oddsThe Inflation Reduction Act subjects JANUVIA, JANUMET, and LENVIMA to U.S. government price setting. Internationally, Germany passed the GKV-BStabG law in July 2026, which will exert significant downward pressure on sales starting in 2027. Lower prices can reduce margins even when prescription demand stays healthy.
Pipeline spending fails to pay off
High impact · Medium oddsMerck is spending heavily to acquire future products, deploying $16 billion in the first half of 2026 for Terns and Cidara. If late-stage data disappoints, the company may spend heavily without filling the late-decade revenue gap.
In one breath
What does Merck make?
Merck makes prescription medicines, vaccines, and animal health products. Its most important product is KEYTRUDA, a cancer drug, but it also sells vaccines like GARDASIL and newer medicines like WINREVAIR and LIPFENDRA.
What is Merck doing about the patent cliffs?
The company is launching new drugs like WINREVAIR and LIPFENDRA. It is also buying other companies, spending $16 billion in early 2026 to acquire Terns and Cidara for their drug pipelines.
Why do WINREVAIR and LIPFENDRA matter so much?
They are Merck's clearest new growth drivers to replace older drugs. WINREVAIR reached $588 million in Q2 2026 sales, and LIPFENDRA gives the company a massive new primary care asset.
What is the main debate on Merck stock?
The debate is whether Merck can replace older product sales fast enough. Bulls point to KEYTRUDA QLEX, new drug launches, and recent acquisitions. Bears point to mid-2026 generic losses and international pricing pressures.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- August 16, 2026
- Score data
- September 6, 2026
- Reviewed by
- Shivam Bharuka
Comparable Drug Manufacturers - General companies
Companies near Merck & Co., Inc. in Finn's Drug Manufacturers - General industry ranking.
